Soluble epoxide hydrolase is a therapeutic target for acute inflammation

Kara R. Schmelzer, Lukas Kubala, John W. Newman, In Hae Kim, Jason P. Eiserich, Bruce D. Hammock

Research output: Contribution to journalArticlepeer-review

352 Scopus citations


As of 2004, >73 million people were prescribed antiinflammatory medication. Despite the extensive number of current products, many people still suffer from their diseases or the pharmacological properties (side effects) of the medications. Therefore, developing therapeutic strategies to treat inflammation remains an important endeavor. Here, we demonstrate that the soluble epoxide hydrolase (sEH) is a key pharmacologic target for treating acute systemic inflammation. Lipopolysaccharide-induced mortality, systemic hypotension, and histologically evaluated tissue injury were substantially diminished by administration of urea-based, small-molecule inhibitors of sEH to C57BL/6 mice. Moreover, sEH inhibitors decreased plasma levels of proinflammatory cytokines and nitric oxide metabolites while promoting the formation of lipoxins, thus supporting inflammatory resolution. These data suggest that sEH inhibitors have therapeutic efficacy in the treatment and management of acute inflammatory diseases.

Original languageEnglish (US)
Pages (from-to)9772-9777
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number28
StatePublished - Jul 12 2005


  • Cydooxygenase
  • Epoxygenase
  • Lipoxin A
  • Lipoxygenase
  • Proinflammatory mediators

ASJC Scopus subject areas

  • Genetics
  • General


Dive into the research topics of 'Soluble epoxide hydrolase is a therapeutic target for acute inflammation'. Together they form a unique fingerprint.

Cite this